GXYLT2 and neoplasm: Taken together, we identified GXYLT2 as a potential prognostic biomarker for GC patients, and targeting GXYLT2 suppressed the tumor aggressiveness and inhibited the Wnt/β-catenin pathway, which may provide a potential therapeutic target for GC patients.